Oculis (NASDAQ:OCS) Hits New 12-Month High – Time to Buy?

Oculis Holding AG (NASDAQ:OCS)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $29.36 and last traded at $29.03, with a volume of 293170 shares. The stock had previously closed at $28.45.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on OCS. Chardan Capital restated a “buy” rating and set a $51.00 price objective on shares of Oculis in a research report on Tuesday, November 11th. Bank of America decreased their target price on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Stifel Nicolaus upped their price objective on shares of Oculis from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Needham & Company LLC restated a “buy” rating and issued a $36.00 target price on shares of Oculis in a report on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Oculis Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. The firm has a market capitalization of $1.52 billion, a PE ratio of -11.52 and a beta of 0.27. The company’s fifty day simple moving average is $22.12 and its 200 day simple moving average is $19.81.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. As a group, equities research analysts expect that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Institutional Trading of Oculis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the period. Marshall Wace LLP purchased a new position in Oculis during the second quarter valued at approximately $393,000. Bosun Asset Management LLC bought a new stake in Oculis during the 2nd quarter worth approximately $378,000. Bank of America Corp DE lifted its stake in Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares in the last quarter. Finally, Woodline Partners LP boosted its holdings in Oculis by 65.8% in the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after purchasing an additional 33,265 shares during the period. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.